Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Michał Marciniec, Anna Szczepańska-Szerej & Konrad Rejdak. (2020) Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin. Neurological Research 42:11, pages 987-991.
Read now
Read now
Michele Poliziani, Marco Koch & Xierong Liu. (2016) Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. Patient Preference and Adherence 10, pages 1601-1608.
Read now
Read now
Wolfgang H Jost, Reiner Benecke, Dieter Hauschke, Joseph Jankovic, Petr Kaňovský, Peter Roggenkämper, David M Simpson & Cynthia L Comella. (2015) Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Design, Development and Therapy 9, pages 1913-1926.
Read now
Read now
Djamel Bensmail, Angelika Hanschmann & Jörg Wissel. (2014) Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). Journal of Medical Economics 17:9, pages 618-625.
Read now
Read now
Allison Brashear. (2013) Treatment of cervical dystonia. Expert Opinion on Orphan Drugs 1:8, pages 599-606.
Read now
Read now
Articles from other publishers (61)
Harald Hefter, Isabelle Schomaecker, Max Schomaecker, Beyza Ürer, Raphaela Brauns, Dietmar Rosenthal, Philipp Albrecht & Sara Samadzadeh. (2023) Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study. Toxins 15:7, pages 431.
Crossref
Crossref
Roberto Erro, Marina Picillo, Maria Teresa Pellecchia & Paolo Barone. (2023) Improving the Efficacy of Botulinum Toxin for Cervical Dystonia: A Scoping Review. Toxins 15:6, pages 391.
Crossref
Crossref
Olivia Samotus & Mandar Jog. (2023)
Conversion to
AbobotulinumtoxinA
Increases Waning Time and Efficacy for Cervical Dystonia
. Movement Disorders Clinical Practice 10:5, pages 756-763.
Crossref
Crossref
Djamel Bensmail, Pierre Karam, Anne Forestier, Jean-Yves Loze & Jonathan Lévy. (2023) Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study. Toxins 15:4, pages 280.
Crossref
Crossref
Harald Hefter, Dietmar Rosenthal, Alexander Jansen, Raphaela Brauns, Beyza Ürer, Hans Bigalke, Hans-Peter Hartung, Sven G. Meuth, John-Ih Lee, Philipp Albrecht & Sara Samadzadeh. (2022) Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. Journal of Neurology 270:2, pages 788-796.
Crossref
Crossref
Delaram Safarpour & Bahman Jabbari. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment
539
555
.
Monika Benson, Alberto Albanese, Kailash P. Bhatia, Pascale Cavillon, Lorraine Cuffe, Kathrin König, Carola Reinhard & Holm Graessner. (2022) Development of a patient journey map for people living with cervical dystonia. Orphanet Journal of Rare Diseases 17:1.
Crossref
Crossref
Grazia Menna, Marco Battistelli, Alessandro Rapisarda, Alessandro Izzo, Manuela D’Ercole, Alessandro Olivi & Nicola Montano. (2022) Factors Related to Hemifacial Spasm Recurrence in Patients Undergoing Microvascular Decompression—A Systematic Review and Meta-Analysis. Brain Sciences 12:5, pages 583.
Crossref
Crossref
Chuenchom Chueluecha & Austen Peter Moore. (2022)
LIVECHART
Patient‐Reported Outcome Tool for Botulinum Toxin Treatment in Cervical Dystonia
. Movement Disorders Clinical Practice 9:2, pages 198-205.
Crossref
Crossref
Cynthia Comella, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Odinachi Oguh, Jennifer Hui, Eric S. Molho, Matthew Brodsky, Erin Furr-Stimming, Georg Comes, Michael A. Hast & David Charles. (2022) Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study. Clinical Parkinsonism & Related Disorders 6, pages 100142.
Crossref
Crossref
A. P. Kovalenko, Z. A. Zalyalova & A. F. Ivolgin. (2021) Novel approaches to the treatment of cervical dystonia. The concept of dual navigation control. Neurology, Neuropsychiatry, Psychosomatics 13:6, pages 124-131.
Crossref
Crossref
Nowell Solish, Jean Carruthers, Joely Kaufman, Roman G. Rubio, Todd M. Gross & Conor J. Gallagher. (2021) Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A. Drugs 81:18, pages 2091-2101.
Crossref
Crossref
Chi Wang Ip, Axel Schramm, Pascal Maisonobe, Emma Zaragatski & Thomas Sycha. (2021) Behandlungszufriedenheit bei Patienten mit zervikaler DystonieTreatment satisfaction in patients with cervical dystonia. Der Nervenarzt 92:12, pages 1268-1275.
Crossref
Crossref
Z. A. Zalyalova & E. R. Iusupova. (2021) Rehabilitation approaches in cervical dystonia. Neurology, Neuropsychiatry, Psychosomatics 13:4, pages 103-108.
Crossref
Crossref
Harald Hefter, Isabelle Schomaecker, Max Schomaecker, Dietmar Rosenthal & Sara Samadzadeh. (2021) The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia. Toxins 13:7, pages 493.
Crossref
Crossref
André Lee, Jabreel Al-Sarea & Eckart Altenmüller. (2021) Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment. Toxins 13:6, pages 371.
Crossref
Crossref
Gamze Kilic-Berkmen, Laura J. Wright, Joel S. Perlmutter, Cynthia Comella, Mark Hallett, Jan Teller, Sarah Pirio Richardson, David A. Peterson, Carlos Cruchaga, Codrin Lungu & H. A. Jinnah. (2021) The Dystonia Coalition: A Multicenter Network for Clinical and Translational Studies. Frontiers in Neurology 12.
Crossref
Crossref
Cynthia Comella, Joaquim J. Ferreira, Emilie Pain, Marion Azoulai & Savary Om. (2020) Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. Journal of Neurology 268:3, pages 903-912.
Crossref
Crossref
Petr Kaňovský, Elie P. Elovic, Angelika Hanschmann, Irena Pulte, Michael Althaus, Reinhard Hiersemenzel & Christina Marciniak. (2021) Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis. Frontiers in Neurology 11.
Crossref
Crossref
Joseph Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn & Jennifer Goldman. 2021. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
353
370.e10
.
Harald Hefter, Isabelle Schomaecker, Max Schomaecker & Sara Samadzadeh. (2020) Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy. Frontiers in Neurology 11.
Crossref
Crossref
Avram Fraint, Glenn T. Stebbins, Gian Pal & Cynthia L. Comella. (2019) Reliability, feasibility and satisfaction of telemedicine evaluations for cervical dystonia. Journal of Telemedicine and Telecare 26:9, pages 560-567.
Crossref
Crossref
Carlo Colosimo, David Charles, Vijay P. Misra, Pascal Maisonobe & Savary Om. (2020) Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study. Journal of the Neurological Sciences 416, pages 117015.
Crossref
Crossref
Anatol Kivi, Songjin Ri & Jörg Wissel. (2020) What clinicians and patients want: The past, the presence, and the future of the botulinum toxins. Toxicon 177, pages 46-51.
Crossref
Crossref
Steven Bellows & Joseph Jankovic. (2020) Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491. Toxins 12:2, pages 72.
Crossref
Crossref
A.F. Ivolgin & T.Y. Avseitseva. (2020) Cervical dystonia: ways to improve the effectiveness of botulinum therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:6, pages 137.
Crossref
Crossref
Richard M. Trosch, Vijay P. Misra, Pascal Maisonobe & Savary Om. (2020) Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice. Clinical Parkinsonism & Related Disorders 3, pages 100063.
Crossref
Crossref
Steven Bellows & Joseph Jankovic. (2020) Treatment of dystonia and tics. Clinical Parkinsonism & Related Disorders 2, pages 12-19.
Crossref
Crossref
Carlo Colosimo, David Charles, Vijay P. Misra, Pascal Maisonobe & Savary Om. (2019) How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. Journal of Neurology 266:12, pages 3038-3046.
Crossref
Crossref
Ayesha Girach, Ana Vinagre Aragon & Panagiotis Zis. (2018) Quality of life in idiopathic dystonia: a systematic review. Journal of Neurology 266:12, pages 2897-2906.
Crossref
Crossref
Steven Bellows & Joseph Jankovic. (2019) Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 11:9, pages 491.
Crossref
Crossref
John C Bladen, Ilan Feldman, Maribel Favor, Marizol Dizon, Andre Litwin & Raman Malhotra. (2018) Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia. Eye 33:3, pages 349-352.
Crossref
Crossref
Harald Hefter, Dietmar Rosenthal, Hans Bigalke & Marek Moll. (2019) Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. Therapeutic Advances in Neurological Disorders 12, pages 175628641989207.
Crossref
Crossref
Talar Tejirian & Louise Yeung. 2019. The SAGES Manual of Hernia Surgery. The SAGES Manual of Hernia Surgery
307
316
.
Talar Tejirian & Louise Yeung. 2019. Robotic Assisted Hernia Repair. Robotic Assisted Hernia Repair
231
242
.
Marek Moll, Dietmar Rosenthal & Harald Hefter. (2018) Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study. Parkinsonism & Related Disorders 57, pages 63-67.
Crossref
Crossref
Jörg Wissel. (2018) Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity – Insights from recent studies. Toxicon 147, pages 100-106.
Crossref
Crossref
H.A. Jinnah, Cynthia L. Comella, Joel Perlmutter, Codrin Lungu & Mark Hallett. (2018) Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?. Toxicon 147, pages 89-95.
Crossref
Crossref
Vijay P. Misra, Carlo Colosimo, David Charles, Tae Mo Chung, Pascal Maisonobe & Savary Om. (2017) INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. Journal of Neurology 265:2, pages 402-409.
Crossref
Crossref
Maria Fiorella Contarino, Joost Van Den Dool, Yacov Balash, Kailash Bhatia, Nir Giladi, Johannes H. Koelman, Annemette Lokkegaard, Maria J. Marti, Miranda Postma, Maja Relja, Matej Skorvanek, Johannes D. Speelman, Evelien Zoons, Joaquim J. Ferreira, Marie Vidailhet, Alberto Albanese & Marina A. J. Tijssen. (2017) Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. Frontiers in Neurology 8.
Crossref
Crossref
Sarah Pirio RichardsonAshley R. WegeleBetty SkipperAmanda DeligtischH.A. JinnahAmi R Rosen, Mark Hallett, Vesper Fe Marie, Jung Park, Karin Mente, Hyunjoo Cho, Elaine Considine, Alfredo Berardelli, Gina Gerrazzano, Scott A Norris, Joel Perlmutter, Laura Wright, Anja Pogarcic, Joseph Jankovic, Laura Marsh, Farah Ismail, Lawrence Severt, Emily Muller, Ludy C Shih, Christine Ashton, Pinky Agarwal, Carey Gonzales, Zoltan Mari, Becky Dunlop, Julie Leegwater-Kim, Caitlin Scopa, Ron Alterman, Steve Frucht, Laurie Ozelius, Kristina Simonyan, Miodrag Velickovic, Ruth Walker, Joan Bratton, Daniel Troung, Trong-Tuong Binh Nguyen, Cynthia Comella, Tracy Waliczek, Tanya Harlow, Stephanie Gonzales, Destini Spaeth, Fatta Nahab, Lissette Moreno, Tao Xie, Joan Young, Alberto J. Espay, Jaya Mishra, Ben Wissel, Brian Berman, Erika Shelton, Irene Malaty, Ramon L. Rodriguez, Kyle Rizer, Amanda Elers, Ergun Uc, Jeri Sieren, Stephen Reich, Katherine Holmes, Richard L. Barbano, Michael Bull, Mark LeDoux, Misty Thompson, Claudia M Testa, Virginia Norris, Daniel Demers, Alison Brashear, Charlotte Miller, Victor SC Fung, Florence Chang, Jane M Griffith, Sylvian Chouinard, Monica Beland, Oksana Suchowersky, Paul McCann, Susan Fox, Brandon Rothberg, Marie Vidailhet, Emmanuel Roze, Cecilia Bonnet, Marta Ruiz, Bertrand Degos, Jean Michel Mayer, Kailash Bhatia, Bettina Balint, Christine Klein, Norbert Brüggemann, Sylwia Dankert, Johanna Junker, Anne Weibach, Natividad Stover, Ashlee Brooke Rawlins, Charles Alder, Amy Duffy, Stephen Grill, Erica Stacy, Joel Blumin, Lynn Wheeler, William Ondo & Chia Arif. (2017) Dystonia treatment. Neurology 88:6, pages 543-550.
Crossref
Crossref
Dhanya Vijayakumar, Subhashie Wijemanne & Joseph Jankovic. (2017) Treatment of blepharospasm with apraclonidine. Journal of the Neurological Sciences 372, pages 57-59.
Crossref
Crossref
Hsin Fen Chien, Ana Lucia Zuma de Rosso, André Sobierajski dos Santos, Carlos Roberto de Mello Rieder, Debora Palma Maia, Delson José da Silva, Marcio da Cunha Andrade, Marcus Vinicius Della Coletta, Maria do Desterro Leiros da Costa, Nasser Allam, Roberto César Pereira do Prado, Vanderci Borges, Vitor Tumas & Wagner de Goes Horta. (2016) Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data. eNeurologicalSci 5, pages 11-14.
Crossref
Crossref
Tobias Ellermeyer, Karen Otte, Felix Heinrich, Sebastian Mansow‐Model, Bastian Kayser, Axel Lipp, Adrian Seidel, Patricia Krause, Katharina Lauritsch, Elona Gusho, Friedemann Paul, Andrea A. Kühn, Alexander U. Brandt & Tanja Schmitz‐Hübsch. (2016) Ranking of Dystonia Severity by Pairwise Video Comparison. Movement Disorders Clinical Practice 3:6, pages 587-595.
Crossref
Crossref
John Fezza, John Burns, Julie Woodward, Daniel Truong, Thomas Hedges & Amit Verma. (2016) A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. Journal of the Neurological Sciences 367, pages 56-62.
Crossref
Crossref
H. A. Jinnah, Emily Goodmann, Ami R. Rosen, Marian Evatt, Alan Freeman & Stewart Factor. (2016) Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. Journal of Neurology 263:6, pages 1188-1194.
Crossref
Crossref
Dominic Tilden & Carmel Guarnieri. (2016) Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia. Value in Health 19:2, pages 145-152.
Crossref
Crossref
Lena Zetterberg, Charlotte Urell & Elisabeth Anens. (2015) Exploring factors related to physical activity in cervical dystonia. BMC Neurology 15:1.
Crossref
Crossref
Oluwadamilola O. Ojo & Hubert H. Fernandez. (2015) Is it time for flexibility in botulinum inter-injection intervals?. Toxicon 107, pages 72-76.
Crossref
Crossref
Alberto Albanese, Giovanni Abbruzzese, Dirk Dressler, Wojciech Duzynski, Svetlana Khatkova, Maria Jose Marti, Pablo Mir, Cesare Montecucco, Elena Moro, Michaela Pinter, Maja Relja, Emmanuel Roze, Inger Marie Skogseid, Sofiya Timerbaeva & Charalampos Tzoulis. (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology 262:10, pages 2201-2213.
Crossref
Crossref
Neera Chaudhry, Abhilekh Srivastava & Laxmikant Joshi. (2015) Hemifacial spasm: The past, present and future. Journal of the Neurological Sciences 356:1-2, pages 27-31.
Crossref
Crossref
Matthias Wittstock. (2015) Behandlungszufriedenheit bei Spastizit?t nach Schlaganfall. DNP - Der Neurologe und Psychiater 16:5, pages 22-23.
Crossref
Crossref
Cynthia Comella & Kailash Bhatia. (2015) An international survey of patients with cervical dystonia. Journal of Neurology 262:4, pages 837-848.
Crossref
Crossref
Virgilio Gerald H. Evidente, Daniel Truong, Joseph Jankovic, Cynthia L. Comella, Susanne Grafe & Angelika Hanschmann. (2014) IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. Journal of the Neurological Sciences 346:1-2, pages 116-120.
Crossref
Crossref
K.D. Sethi & V.G.H. Evidente. (2014) Botulinum toxin treatment using flexible intervals for cervical dystonia. Annals of Physical and Rehabilitation Medicine 57, pages e49-e50.
Crossref
Crossref
Wendy R. Galpern, Christopher S. Coffey, Alberto Albanese, Ken Cheung, Cynthia L. Comella, Dixie J. Ecklund, Stanley Fahn, Joseph Jankovic, Karl Kieburtz, Anthony E. Lang, Michael P. McDermott, Jeremy M. Shefner, Jan K. Teller, John L. P. Thompson, Sharon D. Yeatts & H. A. Jinnah. (2013) Designing Clinical Trials for Dystonia. Neurotherapeutics 11:1, pages 117-127.
Crossref
Crossref
Virgilio Gerald H. Evidente, Hubert H. Fernandez, Mark S. LeDoux, Allison Brashear, Susanne Grafe, Angelika Hanschmann & Cynthia L. Comella. (2013) A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia. Journal of Neural Transmission 120:12, pages 1699-1707.
Crossref
Crossref
Daniel D. Truong, Stephen M. Gollomp, Joseph Jankovic, Peter A. LeWitt, Michael Marx, Angelika Hanschmann & Hubert H. Fernandez. (2013) Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin?) injections in blepharospasm. Journal of Neural Transmission 120:9, pages 1345-1353.
Crossref
Crossref
Alberto Albanese, Francesca Del Sorbo, Cynthia Comella, H. A. Jinnah, Jonathan W. Mink, Bart Post, Marie Vidailhet, Jens Volkmann, Thomas T. Warner, Albert F.G. Leentjens, Pablo Martinez‐Martin, Glenn T. Stebbins, Christopher G. Goetz & Anette Schrag. (2013) Dystonia rating scales: Critique and recommendations. Movement Disorders 28:7, pages 874-883.
Crossref
Crossref
H. A. Jinnah, Alfredo Berardelli, Cynthia Comella, Giovanni DeFazio, Mahlon R. DeLong, Stewart Factor, Wendy R. Galpern, Mark Hallett, Christy L. Ludlow, Joel S. Perlmutter & Ami R. Rosen. (2013) The focal dystonias: Current views and challenges for future research. Movement Disorders 28:7, pages 926-943.
Crossref
Crossref
Joseph Jankovic. (2013) Medical treatment of dystonia. Movement Disorders 28:7, pages 1001-1012.
Crossref
Crossref